ALSO NOTED: FDA panelist rails against lax enforcement; Micromet's CFO resigns;and much more...

> Remember that scathing report from the FDA's own Subcommittee on Science and Technology a couple of weeks ago? One of the Advisory Board members aired his opinion in a written report, and the DrugWonks blog has published it. Report

> Chutes & Ladders: Micromet's CFO Christopher Schnittker has resigned. Donald A. Zelm, Executive Director Finance, will assume the responsibilities as principal financial officer of the Company and as its interim chief financial officer. Release

> Chutes & Ladders: Isis Pharmaceuticals has promoted B. Lynne Parshall, J.D. to COO. Release

> A shocking problem: Patients are trying to figure out whether to live with a recalled Medtronic defibrillator part, or to undergo lengthy, expensive surgery to have their devices replaced. Report

> Little did Pfizer know what it was getting into when it signed an exclusive distribution deal with UniChem in the U.K. The U.S.-based drug maker thought the deal would help it better control supplies, reduce its wholesale discount, and build relationships with pharmacies. Report

> Novartis was hit with two safety-related jabs yesterday. First, the company warned healthcare professionals that its drug Exjade has caused liver failure in some patients. Also, drug watchdogs in the EU want to withdraw all drugs containing the Cox-2 inhibitor Lumiracoxib. Report

And Finally... An FDA advisory panel voted overwhelmingly against allowing Merck to sell its statin Mevacor without a prescription. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.